Search

Displaying results 4021 - 4030 of 5384 in total
  1. Drug

    ATL1101

    go.drugbank.com/drugs/DB05023
    Experimental

    ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis. ATL1101 is being developed as a cream for the topical treatment of...

  2. Drug

    PYM50018

    go.drugbank.com/drugs/DB05126
    Experimental

    PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). In pre-clinical models, PYM50018 has bee...

  3. Drug

    ND7001

    go.drugbank.com/drugs/DB05142
    Experimental

    ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic phosphodiesterase. ...

  4. Drug

    AVAC

    go.drugbank.com/drugs/DB05441
    Experimental

    AVAC is derived from M. vaccae. It has been tested in uses related to asthma and in treating eczema and atopic dermatitis. Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral imm...

  5. Drug

    NOX-700

    go.drugbank.com/drugs/DB05464
    Experimental

    NOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). In animal studies, NOX-700 lowered serum glucose, improved glucose tole...

  6. Drug

    Managlinat dialanetil

    go.drugbank.com/drugs/DB05518
    Investigational

    CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.

  7. Drug

    MBX-2044

    go.drugbank.com/drugs/DB05598
    Investigational

    MBX-2044 was under investigation in clinical trial NCT00422487 (Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes).

  8. Drug

    alpha-Conotoxin VC 1.1

    go.drugbank.com/drugs/DB05724
    Experimental

  9. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to h...

  10. Drug

    CRA-028129

    go.drugbank.com/drugs/DB05951
    Experimental

    CRA-028129 is cathepsin S inhibitor which is under investigation for the treatment of psoriasis.